Cardinal Health grants 54,823 performance units to exec
WEITZMAN DEBORAH reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
WEITZMAN DEBORAH reported acquisition or exercise transactions in this Form 4 filing.
Cardinal Health executive Deborah Weitzman, CEO of the Pharmaceutical & Specialty Solutions segment, received an equity compensation award of 54,823 performance share units on August 4, 2026. These units represent rights to receive common shares and are scheduled to settle on August 15, 2026.
Following this grant, her reported direct holdings in Cardinal Health common shares increased to 107,700 shares. The award was recorded at a price of $0.0000 per share, reflecting that it was a compensation grant rather than an open‑market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Shares F1 | 54,823 | $0.00 | $0.00 |
Footnotes (1)
- F1. Reflects performance share units that will settle on August 15, 2026.
Key Figures
Key Terms
settle financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider equity award did CAH report for Deborah Weitzman?
Was the Cardinal Health (CAH) Form 4 transaction an open-market purchase or a grant?
Is Deborah Weitzman’s CAH equity award reported under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.